DexCom, Inc.

AI-generated fair value estimate for this company.

Method: 10-year FCF DCF: $1.41B TTM free cash flow base; growth 12%/12%/10%/10%/8%/8%/6%/6%/5%/5% across years 1-10; 9% discount rate; 3% terminal growth; +$0.55B net cash; 377.36M shares outstanding.

Reasoning: DexCom has a durable, high-margin, high-growth continuous glucose monitor franchise with secular tailwinds (type 2/pre-diabetes expansion, international rollout). A staged-deceleration FCF DCF fits a profitable, moderate-growth medtech compounder better than a simpler method.